Improving Lives By Protecting Hearing

Spiral is advancing a therapeutic pipeline with focus on balance disorders and hearing loss. Our lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Ménière’s disease.

Learn More

About

40 million people in the US qualify for hearing loss treatment, but there are no drugs approved for hearing loss. Drug delivery to the inner ear remains the largest obstacle.

Precise, non-invasive placement techniques, combined with long-acting delivery systems have the potential to overcome the barriers of drug delivery to the inner ear.

Inflammation and neurodegeneration are the origin of 90% of inner ear disorders. Biomarkers of active disease and improved patient selection are necessary to overcome the challenges of clinical development.

Inspired by ophthalmology, Spiral’s platform addresses hearing loss by delivering the right drugs, to the right place, for the right duration. Our novel drug delivery platform allows for minimally invasive, precise and durable exposure of drugs to the cochlea.

Spiral is advancing a therapeutic pipeline with focus on balance disorders and hearing loss. Our lead program, SPT-2101, is a sustained-release steroid formulation for the treatment of Ménière’s disease.

W3_CORRECTED_badge2023

Team

Executive Team

Hugo Peris

FOUNDER & CEO

Charles Limb, MD

CHIEF MEDICAL OFFICER

Jeffrey Sharon, MD

SVP CLINICAL SCIENCE

Kyle Peterson

CHIEF FINANCIAL OFFICER

Eugene de Juan, MD

EXECUTIVE CHAIRMAN

Linkedin

Benson Jung, PhD

DIRECTOR R&D

Linkedin

Kathy Farinas, PhD

PRINCIPAL SCIENTIST

Linkedin

Richard Yano

RESEARCH ASSOCIATE

Linkedin

Nicola Macfarlane

QUALITY LEAD

Board of Directors

Hugo Peris

FOUNDER & CEO

Angela Macfarlane

INDEPENDENT

Guy Jean Savoir

SAVOIR CAPITAL

Tony Adamis

INDEPENDENT

Eugene de Juan

EXECUTIVE CHAIRMAN

Fred Guerard

INDEPENDENT

Diamantis Xylas

CATALIO CAPITAL

Show Full Team

Technology

Spiral’s MICSTM (minimally-invasive cochlear system) delivery platform is uniquely suited to deliver a wide range of drugs to the ear, with high precision and long duration. Our formulations achieve weeks to months of residence in the middle ear, and can be adapted to deliver drugs with anti-inflammatory, otoprotective and neuroprotective activity for the treatment of balance disorders and hearing loss.

Ménière's disease

Ménière’s disease is a chronic condition characterized by acute vertigo attacks, tinnitus, fluctuating hearing loss and a feeling of aural fullness. Of these symptoms, the vertigo attacks are typically most troubling for patients since they disrupt daily activities and are difficult to anticipate and manage. In general, patients are diagnosed with unilateral Ménière’s disease in middle age and symptoms often continue for decades. Over time, the fluctuating hearing loss becomes permanent in many patients, and a subset of patients will develop symptoms in their second ear. According to the National Institute of Deafness and Other Communication Disorders, there are more than 600,000 patients diagnosed with Ménière’s disease in the United States. There is no known cure for Ménière’s disease and there are currently no FDA-approved drug treatments.

Our lead program, SPT-2101, is currently the subject of an investigational clinical trial in Australia for the treatment of Ménière’s disease. Early data from this trial is showing significant improvement in the frequency of patient reported vertigo episodes and other efficacy outcome measures.

News